Advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression

View Product Pipeline

Advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression

View Product Pipeline
About

We are a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders.

Read More

Product Pipeline


Preclinical
Phase 1
Phase 2
Phase 3
Approved

XEN1101

for Focal Onset Seizures (FOS)
X-TOLE2/3 Clinical Trial

XEN1101

for Primary Generalized Tonic-Clonic Seizures (PGTCS)​
X-ACKT Clinical Trial

XEN1101

for Major Depressive Disorder (MDD)
X-NOVA Clinical trial

XEN1101

for MDD
Investigator-led Phase 2 POC study Collaboration with Mount Sinai

NBI-921352

for Rare Pediatric Epilepsy: SCN8A-DEE
Partnered with Neurocrine Biosciences


Investors

Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events

View Investor Area
Our Management

Learn more about Xenon's management group

View Management
Careers

See current career opportunities

View Careers